06:42:41 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-06-20 Ordinarie utdelning AXIC A 0.00 SEK
2024-06-19 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-06 Extra Bolagsstämma 2024
2024-03-05 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-19 Ordinarie utdelning AXIC A 0.00 SEK
2023-06-16 Årsstämma 2023
2023-05-24 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2022-05-31 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning AXIC A 0.00 SEK
2021-05-28 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning AXIC A 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2018-05-31 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-01 Ordinarie utdelning AXIC A 0.00 SEK
2017-05-31 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-24 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-24 Ordinarie utdelning AXIC A 0.00 SEK
2016-05-23 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-25 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning AXIC A 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-25 Kvartalsrapport 2015-Q1
2015-02-26 Bokslutskommuniké 2014
2014-11-24 Kvartalsrapport 2014-Q3
2014-08-28 Kvartalsrapport 2014-Q2
2014-05-22 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-28 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-08-26 Kvartalsrapport 2013-Q2
2013-06-28 Split AXIC A 4:1
2013-05-30 Kvartalsrapport 2013-Q1
2013-05-21 Ordinarie utdelning AXIC A 0.00 SEK
2013-05-20 Årsstämma 2013
2013-02-28 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-30 Kvartalsrapport 2012-Q2
2012-05-28 Kvartalsrapport 2012-Q1
2012-05-17 Ordinarie utdelning AXIC A 0.00 SEK
2012-05-16 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-28 Kvartalsrapport 2011-Q3
2011-08-30 Kvartalsrapport 2011-Q2
2011-05-30 Kvartalsrapport 2011-Q1
2011-05-10 Ordinarie utdelning AXIC A 0.00 SEK
2011-05-09 Årsstämma 2011
2011-02-25 Bokslutskommuniké 2010
2010-05-11 Ordinarie utdelning AXIC A 0.00 SEK

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorMaterial
IndustriPlast, kemikalier & fetter
aXichem är verksamt inom industriell bioteknik. Bolaget utvecklar, patenterar och marknadsför industrikemikalier. Bolaget arbetar framförallt med Fenylcapsaicin, en naturanalog syntetisk capsaicin med tillämpningar inom en mängd olika områden, såsom inom den marina sektorn, bland skadedjursbekämpning i skogs-och jordbruk, samt bland enskilda farmaceutiska arbetsområden. Verksamhet drivs på global nivå, med huvudkontoret i Malmö.
2023-05-10 08:45:00

aXichem AB (https://www.axichem.com/) (publ), (aXichem), a developer of natural analogue industrial compounds, today announces, building upon the previous breakthrough study, a new clinical trial published in Frontiers, with the title "Effects of phenylcapsaicin on aerobic capacity and physiological parameters in active young males: a randomized, triple-blinded, placebo-controlled, crossover trial" (https://www.frontiersin.org/articles/10.3389/fphys.2023.1190345/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Physiology&id=1190345), adds even more compelling evidence supporting the remarkable benefits of aXivite, a cutting-edge capsaicin analog with enhanced bioavailability. This latest study highlights the potential of aXivite to significantly improve aerobic capacity, substrate oxidation, energy metabolism, and exercise physiological variables in young males.

In this randomized, triple-blinded, placebo-controlled, crossover trial, 17 active males participated in four laboratory sessions. The results showed that both low (0.625 mg) and high (2.5 mg) doses of phenylcapsaicin led to a higher peak of fat oxidation during steady-state tests compared to the placebo. Moreover, the high dose effectively reduced maximum heart rate and optimized perceptual responses during exercise.
These exciting findings demonstrate that aXivite may boost aerobic capacity in athletes by improving fat oxidation, maximum heart rate, and perceptual responses during exercise. Building on the previous study, this new trial further strengthens the scientific foundation supporting aXivite's game-changing potential in the sports performance market.
 

Lucas Altepost, the VP Sales and Marketing at Axichem, remarked:

"At aXichem we take great pride in providing top-quality, scientifically-backed products and as the science behind aXivite continues to solidify, we anticipate significant increase in sales, reflecting the product's potential in the sports performance market."

About phenylcapsaicin and aXivite[®]

aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite[®].

The information was submitted, through the care of the contact person, for publication on 10 May 2023, at 08:45 AM CEST.